Figure 1 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

<p>Identification of Synergistic BH<sub>3</sub>-mimetic–based combinations in LNCaP95 and VCaP-CR Cells. <b>A,</b> Correlation plot depicting DBSumNeg (synergy score) for drugs that pair well with S63845 across LNCaP95 and VCaP-CR lines. <b>B,</b> All pairings of BH<sub>3</sub> mimetics ranked by average DBSumNeg across LNCaP95 and VCaP-CR lines. <b>C</b> to <b>F,</b> Example drug screen data from A-1331852 paired with S63845 in VCaP-CR (<b>C</b> and <b>D</b>) and LNCaP95 (<b>E</b> and <b>F</b>) cells using CellTiter-Glo to measure response. Cell viability (<b>C</b> and <b>E</b>) and Bliss synergy were calculated for each point. Z-plots depict Bliss synergy score at each concentration (<b>D</b> and <b>F</b>). <b>G,</b> Patient mRNA sequencing data from the SU2C 2019 cohort of patients with mCRPC reveals the expression of <i>AR</i>, <i>BCL2</i>, <i>Bcl-xL</i>, and <i>MCL1</i>. Cohort expression was displayed utilizing GraphPad Prism 10, and data are expressed as fragments per kilobase of transcript per million mapped reads (FPKM).</p>